title: The impact of new cancer drugs in real practice oncology: a monoinstitutional experience.
abstract: Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (e.g. value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. We have analyzed a total of 856 cancer patients were registered in the onco-AIFA for various drugs. The results have shown that 38.1% of patients have received only few drug administrations and their treatment was stopped within 4 or 12 weeks (depending on the type of the drug schedule). We have examined the reasons, why their treatment was immediately suspended.
authors.affiliation: Unit of Evaluation and Introduction of New Drugs in Cancer Therapy, Istituto Oncologico Veneto IRCCS of Padua, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Jirillo
authors.forename: Silvia
authors.initials: S
authors.lastname: Imbevaro
authors.forename: Magdalena
authors.initials: M
authors.lastname: Mazurek
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D012042:Registries; D028761:Withholding Treatment / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents